{"id":345194,"date":"2025-08-24T17:27:37","date_gmt":"2025-08-24T17:27:37","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-pyxis-oncology\/"},"modified":"2025-08-24T17:27:37","modified_gmt":"2025-08-24T17:27:37","slug":"how-to-buy-pyxis-oncology","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/","title":{"rendered":"Pyxis Oncology, Inc. (PYXS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Pyxis Oncology, Inc. (PYXS) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334099,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-345194","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Pyxis Oncology, Inc. (PYXS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Pyxis Oncology, Inc. (PYXS) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Pyxis Oncology, Inc. (PYXS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Pyxis Oncology, Inc. (PYXS) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Pyxis Oncology, Inc. (PYXS) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 \u00f6\u011frenin ve analistlere g\u00f6re %547 y\u00fckselme potansiyeline sahip bu umut vadeden biyotek hisse senedinde bilin\u00e7li yat\u0131r\u0131m kararlar\u0131 verin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Pyxis Oncology, Inc. (PYXS) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 \u00f6\u011frenin ve analistlere g\u00f6re %547 y\u00fckselme potansiyeline sahip bu umut vadeden biyotek hisse senedinde bilin\u00e7li yat\u0131r\u0131m kararlar\u0131 verin."},"intro":"Bir sonraki \u00e7\u0131\u011f\u0131r a\u00e7an kanser tedavisine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Pyxis Oncology, klinik deneme ba\u015far\u0131s\u0131n\u0131n m\u00fctevaz\u0131 yat\u0131r\u0131mlar\u0131 hayat de\u011fi\u015ftiren getirilere d\u00f6n\u00fc\u015ft\u00fcrebilece\u011fi heyecan verici biyotek yat\u0131r\u0131m d\u00fcnyas\u0131n\u0131 temsil ediyor. Umut vadeden bir antikor-ila\u00e7 konjugat\u0131 platformu ve stratejik Merck ortakl\u0131\u011f\u0131 ile bu \u015firket, ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in hem y\u00fcksek risk hem de ola\u011fan\u00fcst\u00fc potansiyel \u00f6d\u00fcl sunuyor.","intro_source":{"label":"Intro","type":"text","formatted_value":"Bir sonraki \u00e7\u0131\u011f\u0131r a\u00e7an kanser tedavisine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Pyxis Oncology, klinik deneme ba\u015far\u0131s\u0131n\u0131n m\u00fctevaz\u0131 yat\u0131r\u0131mlar\u0131 hayat de\u011fi\u015ftiren getirilere d\u00f6n\u00fc\u015ft\u00fcrebilece\u011fi heyecan verici biyotek yat\u0131r\u0131m d\u00fcnyas\u0131n\u0131 temsil ediyor. Umut vadeden bir antikor-ila\u00e7 konjugat\u0131 platformu ve stratejik Merck ortakl\u0131\u011f\u0131 ile bu \u015firket, ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in hem y\u00fcksek risk hem de ola\u011fan\u00fcst\u00fc potansiyel \u00f6d\u00fcl sunuyor."},"body_html":"<h2>\ud83d\udcc8 Pyxis Oncology Hisse Senedi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2> <p>24 A\u011fustos 2025 itibar\u0131yla Pyxis Oncology (PYXS) hisseleri <strong>1,24 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>11 Kas\u0131m 2025<\/strong> kesinlikle kritik\u2014Pyxis'in bir sonraki \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayaca\u011f\u0131 tarih.<\/p> <h3>Kazan\u00e7 Raporlar\u0131 PYXS Hissesini Nas\u0131l Hareket Ettirir<\/h3> <p>Biyotek sekt\u00f6r\u00fc klinik deneme g\u00fcncellemeleri ve finansal sonu\u00e7lara ba\u011fl\u0131d\u0131r. Son d\u00f6neme bakarsak:<\/p> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><\/tr> <\/thead> <tbody> <tr><td>14 A\u011fu 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>1,18 $<\/td><td>%5,1 Art\u0131\u015f (kar\u0131\u015f\u0131k tepki)<\/td><\/tr> <tr><td>May\u0131s 2025<\/td><td>AACR Konferans Verileri<\/td><td>0,95 $<\/td><td>%31,6 Art\u0131\u015f (pozitif veri)<\/td><\/tr> <tr><td>\u015eub 2025<\/td><td>Merck Ortakl\u0131\u011f\u0131<\/td><td>1,05 $<\/td><td>%18,1 Art\u0131\u015f (stratejik kazan\u0131m)<\/td><\/tr> <tr><td>Kas 2024<\/td><td>Faz 1 \u0130lk Veriler<\/td><td>1,20 $<\/td><td>%15,0 D\u00fc\u015f\u00fc\u015f (hayal k\u0131r\u0131kl\u0131\u011f\u0131 yaratan sonu\u00e7lar)<\/td><\/tr> <tr><td>A\u011fu 2024<\/td><td>Liderlik De\u011fi\u015fiklikleri<\/td><td>1,35 $<\/td><td>%8,9 D\u00fc\u015f\u00fc\u015f (belirsizlik)<\/td><\/tr> <tr><td>May\u0131s 2024<\/td><td>Preklinik G\u00fcncellemeler<\/td><td>1,10 $<\/td><td>%22,7 Art\u0131\u015f (umut vadeden bilim)<\/td><\/tr> <\/tbody> <\/table> <p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: AACR 2025 gibi pozitif klinik veriler yukar\u0131 y\u00f6nl\u00fc patlay\u0131c\u0131 hareketler yarat\u0131rken, olumsuz deneme sonu\u00e7lar\u0131 an\u0131nda %15-20 d\u00fc\u015f\u00fc\u015flere neden olur. Merck ortakl\u0131\u011f\u0131 ise stratejik anla\u015fmalar\u0131n bilimin yan\u0131 s\u0131ra s\u00fcrd\u00fcr\u00fclebilir ivme sa\u011flad\u0131\u011f\u0131n\u0131 g\u00f6sterdi.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd04 6 Ayl\u0131k Fiyat Yolculu\u011fu (\u015eubat-A\u011fustos 2025)<\/h2> <p>Pyxis hisseleri adeta bir h\u0131z treni yolculu\u011funda:<\/p> <p><strong>\u015eubat<\/strong>: 1,05 $ (Merck ortakl\u0131\u011f\u0131 heyecan\u0131)<br> <strong>Mart<\/strong>: 0,88 $ (piyasa d\u00fczeltmesi, biyotek sekt\u00f6r zay\u0131fl\u0131\u011f\u0131)<br> <strong>Nisan<\/strong>: 0,92 $ (kademeli toparlanma, AACR beklentisi)<br> <strong>May\u0131s<\/strong>: 1,25 $ (AACR pozitif veri a\u00e7\u0131klamas\u0131 +%31,6 art\u0131\u015f)<br> <strong>Haziran<\/strong>: 1,18 $ (kar al\u0131m\u0131, sekt\u00f6r rotasyonu)<br> <strong>Temmuz<\/strong>: 1,15 $ (yaz durgunlu\u011fu, d\u00fc\u015f\u00fck hacim)<br> <strong>A\u011fustos<\/strong>: 1,24 $ (2. \u00e7eyrek kazan\u00e7 istikrar\u0131)<\/p> <p>Hisse bu \u00e7alkant\u0131l\u0131 d\u00f6nemde yakla\u015f\u0131k <strong>%18<\/strong> de\u011fer kazand\u0131, ancak as\u0131l hikaye a\u015f\u0131r\u0131 volatilite\u2014tek ayl\u0131k %30+ dalgalanmalar bu alanda yayg\u0131n.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist projeksiyonlar\u0131 ve klinik pipeline ilerlemesine dayanarak:<\/p> <p><strong>2025 Y\u0131l Sonu<\/strong>: 2,50-3,00 $ (Kas\u0131m klinik g\u00fcncellemeleri bekleniyor) \u2192 <strong>AL<\/strong><br> <strong>2026<\/strong>: 4,00-6,00 $ (Faz 2 verileri bekleniyor, potansiyel ortakl\u0131klar)<br> <strong>2028<\/strong>: 8,00-12,00 $ (Faz 3 ba\u015flang\u0131c\u0131, d\u00fczenleyici kilometre ta\u015flar\u0131)<br> <strong>2030<\/strong>: 15,00-20,00 $ (potansiyel ticarile\u015fme, gelir \u00fcretimi)<\/p> <p><strong>Karar<\/strong>: 2-5 y\u0131ll\u0131k ufku olan risk toleransl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in g\u00fc\u00e7l\u00fc al\u0131m \u00f6nerisi. Mevcut analist ortalama fiyat hedefi <a href=\"https:\/\/stockanalysis.com\/stocks\/pyxs\/forecast\/\">8,67 $ olup %600+ y\u00fckselme potansiyeli<\/a> sunuyor.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Pozitif Sinyaller<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><a href=\"https:\/\/simplywall.st\/stocks\/us\/pharmaceuticals-biotech\/nasdaq-pyxs\/pyxis-oncology\/news\/heres-why-were-watching-pyxis-oncologys-nasdaqpyxs-cash-burn-1\">Mevcut nakit t\u00fcketim h\u0131z\u0131nda sadece 21 ayl\u0131k nakit rezervi<\/a><\/li> <li>Klinik ba\u015far\u0131s\u0131zl\u0131k: Herhangi bir olumsuz deneme verisi hisseyi an\u0131nda %50+ d\u00fc\u015f\u00fcrebilir<\/li> <li>Hisse seyrelme riski: Operasyonlar\u0131 finanse etmek i\u00e7in ikincil halka arz olas\u0131l\u0131\u011f\u0131 y\u00fcksek<\/li> <li>Sekt\u00f6r volatilitesi: Biyotek hisseleri genellikle genel piyasadan 3-5 kat daha fazla dalgalan\u0131r<\/li> <\/ul> <h3>2025-2026 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/02\/04\/3020191\/0\/en\/Pyxis-Oncology-Initiates-New-PYX-201-Combination-Trial-and-Initiates-Cohort-Expansions-of-Ongoing-Monotherapy-Trial.html\">KEYTRUDA ile Faz 1\/2 kombinasyon \u00e7al\u0131\u015fmas\u0131<\/a> aktif olarak hasta al\u0131yor<\/li> <li><a href=\"https:\/\/www.quiverquant.com\/news\/Pyxis+Oncology+Highlights+Promising+Preclinical+Data+for+Micvotabart+Pelidotin+(MICVO)+in+Cancer+Therapy+at+AACR+2025\">MICVO i\u00e7in umut vadeden AACR 2025 preklinik sonu\u00e7lar\u0131<\/a><\/li> <li>Analist deste\u011fi: 3 al\u0131m tavsiyesi, ortalama 8,67 $ fiyat hedefi<\/li> <li>Pazar konumu: Kat\u0131 t\u00fcm\u00f6rleri hedefleyen s\u0131n\u0131f\u0131nda ilk antikor-ila\u00e7 konjugat\u0131<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> - Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3'\u00fcnden fazlas\u0131n\u0131 y\u00fcksek riskli biyotek isimlere ay\u0131rmay\u0131n<\/li> <li><strong>Limit emirleri kullan\u0131n<\/strong> - PYXS gibi volatil hisselerde piyasa emri vermeyin<\/li> <li><strong>Uyar\u0131lar kurun<\/strong> - 11 Kas\u0131m kazan\u00e7lar\u0131 ve klinik deneme duyurular\u0131n\u0131 takip edin<\/li> <li><strong>Zamanlamay\u0131 \u00e7e\u015fitlendirin<\/strong> - Giri\u015f fiyat\u0131n\u0131 ortalamak i\u00e7in \u00f6n\u00fcm\u00fczdeki 3 ayda \u00fc\u00e7te bir oran\u0131nda al\u0131m yapmay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li> <\/ol> <p>Mizahi bir yorum: \"PYXS ticareti yapmak bir t\u0131bbi drama izlemek gibidir\u2014senaryo s\u00fcrprizleri i\u00e7in g\u00fc\u00e7l\u00fc sinirlere ihtiyac\u0131n\u0131z var, ama sezon finali muhte\u015fem olabilir!\"<\/p> <h2>\u2705 Pyxis Oncology, Inc. (PYXS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir ticaret platformu se\u00e7in<\/td><td>NASDAQ listeleri ve par\u00e7al\u0131 hisse sunan platformlar\u0131 tercih edin<\/td><\/tr> <tr><td>2<\/td><td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td><td>\u00c7o\u011fu platform kimlik ve adres kan\u0131t\u0131 ister<\/td><\/tr> <tr><td>3<\/td><td>Fon yat\u0131r\u0131n<\/td><td>Tamamen kaybetmeyi g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>4<\/td><td>\"PYXS\" aramas\u0131 yap\u0131n<\/td><td>\u015eirket ad\u0131 de\u011fil, borsa sembol\u00fcn\u00fc kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td><td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in LIMIT emri kullan\u0131n<\/td><\/tr> <tr><td>6<\/td><td>Hisse miktar\u0131n\u0131 belirleyin<\/td><td>Tam hisse \u00e7ok pahal\u0131ysa par\u00e7al\u0131 hisseyi d\u00fc\u015f\u00fcn\u00fcn<\/td><\/tr> <tr><td>7<\/td><td>\u0130nceleyin ve onaylay\u0131n<\/td><td>Emir detaylar\u0131n\u0131 g\u00f6ndermeden \u00f6nce \u00e7ift kontrol edin<\/td><\/tr> <tr><td>8<\/td><td>Pozisyonu izleyin<\/td><td>Hem yukar\u0131 hem a\u015fa\u011f\u0131 y\u00f6nl\u00fc fiyat uyar\u0131lar\u0131 kurun<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Neden Pocket Option Yeni Biyotek Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Uygun?<\/h2> <p>Pyxis Oncology gibi \u015firketlerle ilgilenenler i\u00e7in Pocket Option birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Minimum depozito sadece 5 $<\/strong> - Volatil hisselerde k\u00fc\u00e7\u00fck pozisyonlarla strateji test etmek i\u00e7in ideal<\/li> <li><strong>H\u0131zl\u0131 do\u011frulama<\/strong> - Tek belge KYC s\u00fcreci ile h\u0131zl\u0131ca ticarete ba\u015flayabilirsiniz<\/li> <li><strong>Par\u00e7al\u0131 hisseler<\/strong> - Pahal\u0131 hisselerin tamam\u0131n\u0131 almadan par\u00e7alar\u0131n\u0131 sat\u0131n al\u0131n<\/li> <li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong> - Karlar\u0131n\u0131z\u0131 \u00e7e\u015fitli kanallardan esnek \u015fekilde \u00e7ekin<\/li> <\/ul> <h2>\ud83c\udf0d Pyxis Oncology 2025'te: Kanser Tedavisinde Yenilik\u00e7i<\/h2> <p>Pyxis Oncology, kat\u0131 t\u00fcm\u00f6rleri hedefleyen yenilik\u00e7i antikor-ila\u00e7 konjugat\u0131 platformu ile kanser tedavisinde devrim yarat\u0131yor. \u015eirketin \u00f6nc\u00fc aday\u0131 MICVO (eski ad\u0131yla PYX-201), tekrarlayan ba\u015f ve boyun kanserlerinin tedavisinde s\u0131n\u0131f\u0131nda ilk yakla\u015f\u0131m\u0131 temsil ediyor.<\/p> <p><strong>2025 e\u011flenceli bilgi<\/strong>: Pyxis bilim insanlar\u0131, antikor platformlar\u0131n\u0131n mevcut tedavilerle kombinasyonda tesad\u00fcfen daha iyi \u00e7al\u0131\u015ft\u0131\u011f\u0131n\u0131 ke\u015ffetti\u2014bu da stratejik Merck ortakl\u0131\u011f\u0131n\u0131n olu\u015fmas\u0131na yol a\u00e7an mutlu bir kazayd\u0131!<\/p> <p>Ticaret stratejileri ve piyasa analizleri hakk\u0131nda daha fazla bilgi i\u00e7in yeni yat\u0131r\u0131mc\u0131lar i\u00e7in haz\u0131rlanm\u0131\u015f e\u011fitim i\u00e7eriklerine <a href=\"\/blog\">Pocket Option blog<\/a> sayfas\u0131ndan ula\u015fabilirsiniz.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Pyxis Oncology Hisse Senedi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2>\n<p>24 A\u011fustos 2025 itibar\u0131yla Pyxis Oncology (PYXS) hisseleri <strong>1,24 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>11 Kas\u0131m 2025<\/strong> kesinlikle kritik\u2014Pyxis&#8217;in bir sonraki \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayaca\u011f\u0131 tarih.<\/p>\n<h3>Kazan\u00e7 Raporlar\u0131 PYXS Hissesini Nas\u0131l Hareket Ettirir<\/h3>\n<p>Biyotek sekt\u00f6r\u00fc klinik deneme g\u00fcncellemeleri ve finansal sonu\u00e7lara ba\u011fl\u0131d\u0131r. Son d\u00f6neme bakarsak:<\/p>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>14 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>1,18 $<\/td>\n<td>%5,1 Art\u0131\u015f (kar\u0131\u015f\u0131k tepki)<\/td>\n<\/tr>\n<tr>\n<td>May\u0131s 2025<\/td>\n<td>AACR Konferans Verileri<\/td>\n<td>0,95 $<\/td>\n<td>%31,6 Art\u0131\u015f (pozitif veri)<\/td>\n<\/tr>\n<tr>\n<td>\u015eub 2025<\/td>\n<td>Merck Ortakl\u0131\u011f\u0131<\/td>\n<td>1,05 $<\/td>\n<td>%18,1 Art\u0131\u015f (stratejik kazan\u0131m)<\/td>\n<\/tr>\n<tr>\n<td>Kas 2024<\/td>\n<td>Faz 1 \u0130lk Veriler<\/td>\n<td>1,20 $<\/td>\n<td>%15,0 D\u00fc\u015f\u00fc\u015f (hayal k\u0131r\u0131kl\u0131\u011f\u0131 yaratan sonu\u00e7lar)<\/td>\n<\/tr>\n<tr>\n<td>A\u011fu 2024<\/td>\n<td>Liderlik De\u011fi\u015fiklikleri<\/td>\n<td>1,35 $<\/td>\n<td>%8,9 D\u00fc\u015f\u00fc\u015f (belirsizlik)<\/td>\n<\/tr>\n<tr>\n<td>May\u0131s 2024<\/td>\n<td>Preklinik G\u00fcncellemeler<\/td>\n<td>1,10 $<\/td>\n<td>%22,7 Art\u0131\u015f (umut vadeden bilim)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: AACR 2025 gibi pozitif klinik veriler yukar\u0131 y\u00f6nl\u00fc patlay\u0131c\u0131 hareketler yarat\u0131rken, olumsuz deneme sonu\u00e7lar\u0131 an\u0131nda %15-20 d\u00fc\u015f\u00fc\u015flere neden olur. Merck ortakl\u0131\u011f\u0131 ise stratejik anla\u015fmalar\u0131n bilimin yan\u0131 s\u0131ra s\u00fcrd\u00fcr\u00fclebilir ivme sa\u011flad\u0131\u011f\u0131n\u0131 g\u00f6sterdi.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd04 6 Ayl\u0131k Fiyat Yolculu\u011fu (\u015eubat-A\u011fustos 2025)<\/h2>\n<p>Pyxis hisseleri adeta bir h\u0131z treni yolculu\u011funda:<\/p>\n<p><strong>\u015eubat<\/strong>: 1,05 $ (Merck ortakl\u0131\u011f\u0131 heyecan\u0131)<br \/> <strong>Mart<\/strong>: 0,88 $ (piyasa d\u00fczeltmesi, biyotek sekt\u00f6r zay\u0131fl\u0131\u011f\u0131)<br \/> <strong>Nisan<\/strong>: 0,92 $ (kademeli toparlanma, AACR beklentisi)<br \/> <strong>May\u0131s<\/strong>: 1,25 $ (AACR pozitif veri a\u00e7\u0131klamas\u0131 +%31,6 art\u0131\u015f)<br \/> <strong>Haziran<\/strong>: 1,18 $ (kar al\u0131m\u0131, sekt\u00f6r rotasyonu)<br \/> <strong>Temmuz<\/strong>: 1,15 $ (yaz durgunlu\u011fu, d\u00fc\u015f\u00fck hacim)<br \/> <strong>A\u011fustos<\/strong>: 1,24 $ (2. \u00e7eyrek kazan\u00e7 istikrar\u0131)<\/p>\n<p>Hisse bu \u00e7alkant\u0131l\u0131 d\u00f6nemde yakla\u015f\u0131k <strong>%18<\/strong> de\u011fer kazand\u0131, ancak as\u0131l hikaye a\u015f\u0131r\u0131 volatilite\u2014tek ayl\u0131k %30+ dalgalanmalar bu alanda yayg\u0131n.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist projeksiyonlar\u0131 ve klinik pipeline ilerlemesine dayanarak:<\/p>\n<p><strong>2025 Y\u0131l Sonu<\/strong>: 2,50-3,00 $ (Kas\u0131m klinik g\u00fcncellemeleri bekleniyor) \u2192 <strong>AL<\/strong><br \/> <strong>2026<\/strong>: 4,00-6,00 $ (Faz 2 verileri bekleniyor, potansiyel ortakl\u0131klar)<br \/> <strong>2028<\/strong>: 8,00-12,00 $ (Faz 3 ba\u015flang\u0131c\u0131, d\u00fczenleyici kilometre ta\u015flar\u0131)<br \/> <strong>2030<\/strong>: 15,00-20,00 $ (potansiyel ticarile\u015fme, gelir \u00fcretimi)<\/p>\n<p><strong>Karar<\/strong>: 2-5 y\u0131ll\u0131k ufku olan risk toleransl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in g\u00fc\u00e7l\u00fc al\u0131m \u00f6nerisi. Mevcut analist ortalama fiyat hedefi <a href=\"https:\/\/stockanalysis.com\/stocks\/pyxs\/forecast\/\">8,67 $ olup %600+ y\u00fckselme potansiyeli<\/a> sunuyor.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Pozitif Sinyaller<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><a href=\"https:\/\/simplywall.st\/stocks\/us\/pharmaceuticals-biotech\/nasdaq-pyxs\/pyxis-oncology\/news\/heres-why-were-watching-pyxis-oncologys-nasdaqpyxs-cash-burn-1\">Mevcut nakit t\u00fcketim h\u0131z\u0131nda sadece 21 ayl\u0131k nakit rezervi<\/a><\/li>\n<li>Klinik ba\u015far\u0131s\u0131zl\u0131k: Herhangi bir olumsuz deneme verisi hisseyi an\u0131nda %50+ d\u00fc\u015f\u00fcrebilir<\/li>\n<li>Hisse seyrelme riski: Operasyonlar\u0131 finanse etmek i\u00e7in ikincil halka arz olas\u0131l\u0131\u011f\u0131 y\u00fcksek<\/li>\n<li>Sekt\u00f6r volatilitesi: Biyotek hisseleri genellikle genel piyasadan 3-5 kat daha fazla dalgalan\u0131r<\/li>\n<\/ul>\n<h3>2025-2026 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/02\/04\/3020191\/0\/en\/Pyxis-Oncology-Initiates-New-PYX-201-Combination-Trial-and-Initiates-Cohort-Expansions-of-Ongoing-Monotherapy-Trial.html\">KEYTRUDA ile Faz 1\/2 kombinasyon \u00e7al\u0131\u015fmas\u0131<\/a> aktif olarak hasta al\u0131yor<\/li>\n<li><a href=\"https:\/\/www.quiverquant.com\/news\/Pyxis+Oncology+Highlights+Promising+Preclinical+Data+for+Micvotabart+Pelidotin+(MICVO)+in+Cancer+Therapy+at+AACR+2025\">MICVO i\u00e7in umut vadeden AACR 2025 preklinik sonu\u00e7lar\u0131<\/a><\/li>\n<li>Analist deste\u011fi: 3 al\u0131m tavsiyesi, ortalama 8,67 $ fiyat hedefi<\/li>\n<li>Pazar konumu: Kat\u0131 t\u00fcm\u00f6rleri hedefleyen s\u0131n\u0131f\u0131nda ilk antikor-ila\u00e7 konjugat\u0131<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> &#8211; Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3&#8217;\u00fcnden fazlas\u0131n\u0131 y\u00fcksek riskli biyotek isimlere ay\u0131rmay\u0131n<\/li>\n<li><strong>Limit emirleri kullan\u0131n<\/strong> &#8211; PYXS gibi volatil hisselerde piyasa emri vermeyin<\/li>\n<li><strong>Uyar\u0131lar kurun<\/strong> &#8211; 11 Kas\u0131m kazan\u00e7lar\u0131 ve klinik deneme duyurular\u0131n\u0131 takip edin<\/li>\n<li><strong>Zamanlamay\u0131 \u00e7e\u015fitlendirin<\/strong> &#8211; Giri\u015f fiyat\u0131n\u0131 ortalamak i\u00e7in \u00f6n\u00fcm\u00fczdeki 3 ayda \u00fc\u00e7te bir oran\u0131nda al\u0131m yapmay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li>\n<\/ol>\n<p>Mizahi bir yorum: &#8220;PYXS ticareti yapmak bir t\u0131bbi drama izlemek gibidir\u2014senaryo s\u00fcrprizleri i\u00e7in g\u00fc\u00e7l\u00fc sinirlere ihtiyac\u0131n\u0131z var, ama sezon finali muhte\u015fem olabilir!&#8221;<\/p>\n<h2>\u2705 Pyxis Oncology, Inc. (PYXS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir ticaret platformu se\u00e7in<\/td>\n<td>NASDAQ listeleri ve par\u00e7al\u0131 hisse sunan platformlar\u0131 tercih edin<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td>\n<td>\u00c7o\u011fu platform kimlik ve adres kan\u0131t\u0131 ister<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Fon yat\u0131r\u0131n<\/td>\n<td>Tamamen kaybetmeyi g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>&#8220;PYXS&#8221; aramas\u0131 yap\u0131n<\/td>\n<td>\u015eirket ad\u0131 de\u011fil, borsa sembol\u00fcn\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in LIMIT emri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Hisse miktar\u0131n\u0131 belirleyin<\/td>\n<td>Tam hisse \u00e7ok pahal\u0131ysa par\u00e7al\u0131 hisseyi d\u00fc\u015f\u00fcn\u00fcn<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>\u0130nceleyin ve onaylay\u0131n<\/td>\n<td>Emir detaylar\u0131n\u0131 g\u00f6ndermeden \u00f6nce \u00e7ift kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>Pozisyonu izleyin<\/td>\n<td>Hem yukar\u0131 hem a\u015fa\u011f\u0131 y\u00f6nl\u00fc fiyat uyar\u0131lar\u0131 kurun<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Neden Pocket Option Yeni Biyotek Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Uygun?<\/h2>\n<p>Pyxis Oncology gibi \u015firketlerle ilgilenenler i\u00e7in Pocket Option birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Minimum depozito sadece 5 $<\/strong> &#8211; Volatil hisselerde k\u00fc\u00e7\u00fck pozisyonlarla strateji test etmek i\u00e7in ideal<\/li>\n<li><strong>H\u0131zl\u0131 do\u011frulama<\/strong> &#8211; Tek belge KYC s\u00fcreci ile h\u0131zl\u0131ca ticarete ba\u015flayabilirsiniz<\/li>\n<li><strong>Par\u00e7al\u0131 hisseler<\/strong> &#8211; Pahal\u0131 hisselerin tamam\u0131n\u0131 almadan par\u00e7alar\u0131n\u0131 sat\u0131n al\u0131n<\/li>\n<li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong> &#8211; Karlar\u0131n\u0131z\u0131 \u00e7e\u015fitli kanallardan esnek \u015fekilde \u00e7ekin<\/li>\n<\/ul>\n<h2>\ud83c\udf0d Pyxis Oncology 2025&#8217;te: Kanser Tedavisinde Yenilik\u00e7i<\/h2>\n<p>Pyxis Oncology, kat\u0131 t\u00fcm\u00f6rleri hedefleyen yenilik\u00e7i antikor-ila\u00e7 konjugat\u0131 platformu ile kanser tedavisinde devrim yarat\u0131yor. \u015eirketin \u00f6nc\u00fc aday\u0131 MICVO (eski ad\u0131yla PYX-201), tekrarlayan ba\u015f ve boyun kanserlerinin tedavisinde s\u0131n\u0131f\u0131nda ilk yakla\u015f\u0131m\u0131 temsil ediyor.<\/p>\n<p><strong>2025 e\u011flenceli bilgi<\/strong>: Pyxis bilim insanlar\u0131, antikor platformlar\u0131n\u0131n mevcut tedavilerle kombinasyonda tesad\u00fcfen daha iyi \u00e7al\u0131\u015ft\u0131\u011f\u0131n\u0131 ke\u015ffetti\u2014bu da stratejik Merck ortakl\u0131\u011f\u0131n\u0131n olu\u015fmas\u0131na yol a\u00e7an mutlu bir kazayd\u0131!<\/p>\n<p>Ticaret stratejileri ve piyasa analizleri hakk\u0131nda daha fazla bilgi i\u00e7in yeni yat\u0131r\u0131mc\u0131lar i\u00e7in haz\u0131rlanm\u0131\u015f e\u011fitim i\u00e7eriklerine <a href=\"\/blog\">Pocket Option blog<\/a> sayfas\u0131ndan ula\u015fabilirsiniz.<\/p>\n"},"faq":[{"question":"Pyxis Oncology hisseleri nereden al\u0131nabilir?","answer":"Pyxis Oncology hisseleri NASDAQ borsas\u0131nda PYXS sembol\u00fc ile i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden al\u0131m yapabilirsiniz."},{"question":"Pyxis Oncology'nin riskleri nelerdir?","answer":"\u015eirketin nakit rezervleri s\u0131n\u0131rl\u0131, klinik denemelerde ba\u015far\u0131s\u0131zl\u0131k riski y\u00fcksek ve hisse seyrelme olas\u0131l\u0131\u011f\u0131 bulunmaktad\u0131r. Ayr\u0131ca biyotek sekt\u00f6r\u00fc y\u00fcksek volatiliteye sahiptir."},{"question":"Pyxis Oncology'nin gelecekteki fiyat tahmini nedir?","answer":"Analistlere g\u00f6re 2025 sonunda hisse fiyat\u0131 2,50-3,00 $ aral\u0131\u011f\u0131nda, 2030 y\u0131l\u0131nda ise 15,00-20,00 $ aras\u0131nda olabilir."},{"question":"Yeni ba\u015flayanlar Pyxis Oncology hissesi al\u0131rken nelere dikkat etmeli?","answer":"Portf\u00f6y\u00fcn k\u00fc\u00e7\u00fck bir k\u0131sm\u0131n\u0131 ay\u0131rmak, limit emirleri kullanmak, fiyat uyar\u0131lar\u0131 kurmak ve al\u0131mlar\u0131 zaman i\u00e7inde da\u011f\u0131tmak \u00f6nemlidir."},{"question":"Pocket Option Pyxis Oncology yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama, par\u00e7al\u0131 hisse al\u0131m\u0131 ve \u00e7ok say\u0131da para \u00e7ekme y\u00f6ntemi sunmas\u0131 nedeniyle yeni biyotek yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in idealdir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Pyxis Oncology hisseleri nereden al\u0131nabilir?","answer":"Pyxis Oncology hisseleri NASDAQ borsas\u0131nda PYXS sembol\u00fc ile i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden al\u0131m yapabilirsiniz."},{"question":"Pyxis Oncology'nin riskleri nelerdir?","answer":"\u015eirketin nakit rezervleri s\u0131n\u0131rl\u0131, klinik denemelerde ba\u015far\u0131s\u0131zl\u0131k riski y\u00fcksek ve hisse seyrelme olas\u0131l\u0131\u011f\u0131 bulunmaktad\u0131r. Ayr\u0131ca biyotek sekt\u00f6r\u00fc y\u00fcksek volatiliteye sahiptir."},{"question":"Pyxis Oncology'nin gelecekteki fiyat tahmini nedir?","answer":"Analistlere g\u00f6re 2025 sonunda hisse fiyat\u0131 2,50-3,00 $ aral\u0131\u011f\u0131nda, 2030 y\u0131l\u0131nda ise 15,00-20,00 $ aras\u0131nda olabilir."},{"question":"Yeni ba\u015flayanlar Pyxis Oncology hissesi al\u0131rken nelere dikkat etmeli?","answer":"Portf\u00f6y\u00fcn k\u00fc\u00e7\u00fck bir k\u0131sm\u0131n\u0131 ay\u0131rmak, limit emirleri kullanmak, fiyat uyar\u0131lar\u0131 kurmak ve al\u0131mlar\u0131 zaman i\u00e7inde da\u011f\u0131tmak \u00f6nemlidir."},{"question":"Pocket Option Pyxis Oncology yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama, par\u00e7al\u0131 hisse al\u0131m\u0131 ve \u00e7ok say\u0131da para \u00e7ekme y\u00f6ntemi sunmas\u0131 nedeniyle yeni biyotek yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in idealdir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pyxis Oncology, Inc. (PYXS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Pyxis Oncology, Inc. (PYXS) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pyxis Oncology, Inc. (PYXS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Pyxis Oncology, Inc. (PYXS) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-24T17:27:37+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Pyxis Oncology, Inc. (PYXS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Pyxis Oncology, Inc. (PYXS) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-24T17:27:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/\",\"name\":\"Pyxis Oncology, Inc. (PYXS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Pyxis Oncology, Inc. (PYXS) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"datePublished\":\"2025-08-24T17:27:37+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pyxis Oncology, Inc. (PYXS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Pyxis Oncology, Inc. (PYXS) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pyxis Oncology, Inc. (PYXS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Pyxis Oncology, Inc. (PYXS) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/","og_locale":"tr_TR","og_type":"article","og_title":"Pyxis Oncology, Inc. (PYXS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Pyxis Oncology, Inc. (PYXS) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-24T17:27:37+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Pyxis Oncology, Inc. (PYXS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Pyxis Oncology, Inc. (PYXS) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-24T17:27:37+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/","name":"Pyxis Oncology, Inc. (PYXS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Pyxis Oncology, Inc. (PYXS) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","datePublished":"2025-08-24T17:27:37+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pyxis-oncology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Pyxis Oncology, Inc. (PYXS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Pyxis Oncology, Inc. (PYXS) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":345190,"slug":"how-to-buy-pyxis-oncology","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Pyxis Oncology, Inc. (PYXS) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Pyxis Oncology, Inc. (PYXS)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-pyxis-oncology\/"},"pt_AA":{"locale":"pt_AA","id":345193,"slug":"how-to-buy-pyxis-oncology","post_title":"Como comprar a\u00e7\u00f5es da Pyxis Oncology, Inc. (PYXS) - Investimento em a\u00e7\u00f5es da Pyxis Oncology, Inc. (PYXS)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-pyxis-oncology\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/345194","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=345194"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/345194\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334099"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=345194"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=345194"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=345194"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}